Compare CARE & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CARE | BWAY |
|---|---|---|
| Founded | 1974 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.9M | 450.8M |
| IPO Year | 2020 | N/A |
| Metric | CARE | BWAY |
|---|---|---|
| Price | $20.14 | $13.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | ★ 160.5K | 132.1K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.19 | N/A |
| EPS | ★ 1.38 | N/A |
| Revenue | ★ $20,315,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.72 | $24.33 |
| P/E Ratio | ★ $14.54 | $81.98 |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $13.61 | $7.84 |
| 52 Week High | $22.51 | $26.63 |
| Indicator | CARE | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 29.39 |
| Support Level | $19.32 | $11.55 |
| Resistance Level | $20.36 | $17.20 |
| Average True Range (ATR) | 0.62 | 1.05 |
| MACD | -0.14 | -0.64 |
| Stochastic Oscillator | 26.42 | 14.18 |
Carter Bankshares Inc is a bank holding company that conducts its business solely through the bank. The Bank earns revenue from interest on loans and securities and fees charged for financial services provided to customers. It offers a full range of deposit services including Lifetime Free Checking, interest checking accounts, savings accounts, retirement accounts and other deposit accounts of various types, ranging from money market accounts to longer-term CDs. The Bank offers a full range of commercial and consumer loans. The Bank also originates and holds fixed and variable-rate mortgage loans and offers home equity lines of credit to its customers.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.